Meeting
2023 ASCO Annual Meeting
Methylation-based prediction of myelodysplastic syndrome survival outcomes.
Authors
Alvin Shi
GRAIL, LLC, a subsidiary of Illumina, Inc., currently held separate from Illumina, Inc., under the terms of the Interim Measures Order of the European Commission dated 29 October 2021, Menlo Park, CA
Alvin Shi , Abdullah Ali , Gordon Cann , Rita Shaknovich , Oliver Venn , Azra Raza , Qinwen Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myelodysplastic Syndromes (MDS)
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7058)
DOI
10.1200/JCO.2023.41.16_suppl.7058
Abstract #
7058
Poster Bd #
188
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat.
First Author: Koichi Takahashi
Poster
2016 ASCO Annual Meeting
Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.
First Author: Maro Ohanian
Poster
2023 ASCO Annual Meeting
A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.
First Author: Maha AT Elsebaie
Poster
2022 ASCO Annual Meeting
Comparative genomic analysis and its prognostic impact on survival between viral hepatitis-related and non-viral hepatitis intrahepatic cholangiocarcinoma.
First Author: Nai-Jung Chiang